For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Healing & Recovery

KPV

Also known as: Lysine-Proline-Valine (alpha-MSH 11-13)

KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH), corresponding to residues 11-13. It is the smallest alpha-MSH fragment shown to retain anti-inflammatory activity. Research-only; not FDA-approved; evidence is primarily preclinical.

Where to buy · live market data

Who's worth your money for KPV

Every current seller, ranked by independent evidence — Merit Score, latest COA purity, and live $/mg (size-normalized). Prices refresh daily. Rankings are never paid.

Top Merit pick

Highest Merit Score (99) of 40 scored sellers

$3.20/mg

$320 · 100mg · 99.4% purity

Best value

Lowest $/mg among scored sellers

$0.83/mg

$250 · 300mg · 99.4% purity

Most tested

17 independent COAs on file

$5.50/mg

$55.00 · 10mg · 98.5% purity

Average price

$5.32/mg

Sellers

74

45-day trend

-14.8%

61 of 74 sellers have a current price· 3 stale hidden· 18 unverified hidden

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Watch KPV

Get one email when the market actually moves — no newsletter, no noise.

Compound reference

About KPV

CAS

67727-97-3

Molecular formula

C16H30N4O4

Sequence

KPV

Typical dose range

250–500 mcg/day subcutaneous (research use)

Half-life

~4–6 hours (rodent pharmacokinetic data; human data lacking)

Independent evidence

COAs for KPV

176 third-party tests across 42 vendors. Each card links to the full report.

All 176 COAs for KPV →
Measured purity 97.8%–100.0% across 121 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.84 %
Sep 2026
Freedom Diagnostics Moderate

For

KPV

by Peptide Plugs· batch 1130L-DK

Aggregated · 3rd-party listing
98.79 %
Sep 2026
Janoshik Analytical Limited

For

KPV

by CertaPeptides· batch CP-2607-KPV10

Aggregated · 3rd-party listing
99.79 %
Sep 2026
Freedom Diagnostics Moderate

For

KPV

by Forge Performance Co.· batch KPV10-2609-01-BLU-SLV

Aggregated · 3rd-party listing
99.59 %
Sep 2026
Freedom Diagnostics Moderate

For

KPV

by Peptide Plugs· batch 71110L-DK

Aggregated · 3rd-party listing
99.84 %
Sep 2026
Freedom Diagnostics Moderate

For

KPV

by Rescue Research USA· batch RR-KPV-2609

Aggregated · 3rd-party listing
99.29 %
Aug 2026
ILS Labs Strong

For

KPV

by Velora Biolabs· batch VBL-KPV10-1

Aggregated · 3rd-party listing
99.63 %
Aug 2026
Freedom Diagnostics Moderate

For

KPV

by Synthesis Peptides· batch KPV10926

Aggregated · 3rd-party listing
99.41 %
Aug 2026
ILS Labs Strong

For

KPV

by Sunrise Bioresearch· batch KPVJUN26-01

✓ Vendor-published
99.41 %
Aug 2026
ILS Laboratories

For

KPV

by Sunrise Bioresearch· batch KPVJUN26-01

COA on file
Aggregated · 3rd-party listing
98.20 %
Aug 2026
Krause Analytical

For

KPV

by VoriLabs· batch VoriLabs KPV-2607-A

Aggregated · 3rd-party listing
99.81 %
Jul 2026
ILS Labs Strong

For

KPV

by jdbioworks· batch 2026-002

Aggregated · 3rd-party listing
99.60 %
Jul 2026
ILS Labs Strong

For

KPV

by Artisan Aminos· batch AA-KPV10-049

Aggregated · 3rd-party listing
99.66 %
Jul 2026
ILS Labs Strong

For

KPV

by NG Peptide· batch KP10-06

Aggregated · 3rd-party listing
99.49 %
Jul 2026
Freedom Diagnostics Moderate

For

KPV

by Peptide Plugs· batch 101-05-ZB

Aggregated · 3rd-party listing
99.00 %
Jul 2026
ILS Labs Strong

For

KPV

by Ignite Peptides· batch KPV1012321

Aggregated · 3rd-party listing
99.00 %
Jun 2026
Ethos Analytics Strong

For

KPV

by OROS Research· batch OR-LPKPV15-626-B3

Aggregated · 3rd-party listing
98.16 %
Jun 2026
Janoshik Analytical Limited

For

KPV

by Optima Supply· batch OS-2026-1179

Aggregated · 3rd-party listing
98.16 %
Jun 2026
Janoshik Analytical Limited

For

KPV

by Hydro Research Peptides· batch HR-2026-4981

✓ Vendor-published
98.16 %
Jun 2026
Janoshik Analytical Limited

For

KPV

by optimasupply.is· batch OS-2026-1179

COA on file
Aggregated · 3rd-party listing
99.60 %
Jun 2026
Freedom Diagnostics Moderate

For

KPV

by Apexx Biolabs· batch Purple Cap-1

Aggregated · 3rd-party listing
99.71 %
Jun 2026
ILS Labs Strong

For

KPV

by Mile High Compounds· batch KPV-010-MH-05

Aggregated · 3rd-party listing
98.49 %
Jun 2026
Prime Analytical Laboratories, LLC

For

KPV

by Soma Peptides· batch KPX062609

✓ Vendor-published
99.39 %
Jun 2026
TrustPointe Analytics Moderate

For

KPV

by Peptide Partners· batch SPL-4157

COA on file
✓ Vendor-published
99.70 %
Jun 2026
Kovera Labs

For

KPV

by Peptide Partners· batch KV202606

COA on file
Research depth

12 citations indexed for KPV

All research on KPV →

Study · 2026

Lysine-Proline-Valine attenuates oxidized low-density lipoprotein-induced foam cell formation and inflammatory responses in RAW264.7 macrophages

Atherosclerosis develops through oxidative stress and inflammatory responses induced by oxidized low-density lipoprotein (oxLDL), and excessive lipid accumulation in macrophages accelerates disease progression by facilitating foam cell formation.

animal · 2026

KPV attenuates adipogenesis and lipid metabolism through modulation of ROS-mediated AKT/mTORC1/PPARγ signaling

Lysine-Proline-Valine (KPV), an endogenous tripeptide derived from α-melanocyte-stimulating hormone, has been recognized for its anti-inflammatory and antioxidant activities. However, its role in adipocyte differentiation has not been investigated.

Study · 2026

Lysine-proline-valine peptide attenuates hepatic lipid accumulation through ROS-dependent regulation of the PPARγ pathway in HepG2 cells

Hepatocellular steatosis, an early stage within the non-alcoholic fatty liver disease (NAFLD) spectrum, is characterized by excessive lipid accumulation and oxidative stress in hepatocytes.

Study · 2026

Inflammation-triggered self-immolative conjugates enable oral peptide delivery by overcoming gastrointestinal barriers

Oral delivery of peptide therapeutics remains challenging due to gastrointestinal (GI) degradation and poor intestinal absorption.

in-vitro · 2026

Exploration of 1,3,4-Thiadiazole Bearing Quinolin-2(1H)-One Hybrids as Potent Antimycobacterial Agents: Design, Synthesis, and In Silico Docking Techniques

Introduction The development of novel quinolin-2(1H)-one-fused 1,3,4-thiadiazole heterocyclic hybrids was achieved through structural optimization as potential antimicrobial/anti- TB agents.

review · 2026

Synthetic Peptides in Pharmacy Compounding: Analysis of PCAC Recommendations and Industry Safety Standards

Compounded peptides have quickly moved from a niche topic to a growing area of interest among patients and prescribers. These products are promoted for a wide range of uses, including tissue repair, inflammation, metabolic health, and healthy aging.